Halozyme to acquire antares pharma to create a specialty product and drug delivery leader

Transaction expected to be immediately accretive to revenue and non-gaap earnings in 2022 with multiple drivers to accelerate financial growth through 2027 and beyond augments drug delivery business with best-in-class auto injector platform with broad licensing potential diversifies revenue mix with addition of growing testosterone replacement therapy product revenues to anchor commercial opportunity with key targeted audiences creates a leading drug delivery business with broadly licensable opportunities across enhanze and antares auto injector platforms halozyme to host conference call and webcast today at 8:00 a.m. et/5:00 a.m.
ATRS Ratings Summary
ATRS Quant Ranking